• Explore /
  • Poster
  • / Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).

Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).

Abstract Poster

Authors

null

Changhoon Yoo

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)

Changhoon Yoo , Kyu-Pyo Kim , Ki Byung Song , Sang Soo Lee , Do Hyun Park , Tae Jun Song , Seung Soo Lee , Jin-hong Park , Dae Wook Hwang , Jae Hoon Lee , Sang Hyun Shin , Eunseon Shin , Baek-Yeol Ryoo , Song Cheol Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02749136

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 342)

DOI

10.1200/JCO.2019.37.4_suppl.342

Abstract #

342

Poster Bd #

H20

Abstract Disclosures

Similar Posters

First Author: Dong Ho Lee

First Author: Nai-Jung Chiang

First Author: Sherise C. Rogers

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).

Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).

First Author: Fergus Keane